DGAP-News

Vita 34 AG Publishes Financial Figures for the First Half-Year 2014 - Seite 2

measures introduced in 2013. In particular, the selling expenses were
reduced by EUR 0.2 million to EUR 2.2 million by means of more efficient
marketing. Costs incurred in the stellacure subsidiary and remuneration
expense vis-a-vis a former Management Board member led to a one-time
increase in administrative costs to EUR 1.4 million (prior year: EUR 1.3
million). Earnings before interest, taxes, depreciation and amortization
(EBITDA) were EUR 0.8 million in the first half-year 2014, nearly the prior
year's level (first half-year 2013: EUR 0.9 million). Measured on revenues
Vita 34 earned an EBITDA margin of 13.4 percent (first half-year 2013: 13.8
percent). EBIT was also stable as compared with the prior year at EUR 0.3
million, and the group result was increased by 67 percent to EUR 114k in
the first half-year 2014 (first half-year 2013: EUR 68k).

Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, commented:
"Even if we have not yet attained the planned increase in profits in the
reporting period, we consider ourselves to be well positioned to shape the
development of Vita 34 in a positive and sustainably profitable manner on
an ongoing basis. In the long term, we will energetically pursue the
development from an umbilical cord blood bank to a service provider and
supplier of cell products for pharmaceutical manufacturing. For the second
half-year of 2014 Vita 34 is faced, in particular, with the challenge of
increasing the number of new storages and the associated revenues. We have
already initiated corresponding measures, and will implement them
consistently."

Vita 34 will approach expecting parents in an even more targeted manner
using efficient marketing and sales measures. The new Internet presence
that is optimized for mobile devices, the introduction of the Vita 34 "Our
Baby" app, as well as the "Thanks Mama" advertising campaign are examples
of a series of measures undertaken in the area of marketing and sales. Vita
34 expects a contribution to the expansion of our market position in the
German-speaking countries from the newly hired Managing Director for our
Austrian subsidiary. Vita 34 has further expanded activities in the
Biotechnology segment during the reporting period with research projects
involving the cryo-preservation of autologous fatty tissue, as well as the
development of processes for the optimized extraction of plant agents. This
opens the potential to Vita 34 of participating in new discoveries and
product innovations, and expanding our own product range.

Following the first half-year, the company is confident of being able to